» Positive Early Results For Phase 2 Clinical Trial Of VX-770 For Cystic Fibrosis
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients…